(PharmaNewsWire.Com, November 03, 2017 ) According to Publisher, the Global Viral Inactivation Market is accounted for $1.99 billion in 2016 and expected to grow at a CAGR of 14.9% to reach $5.29 billion by 2023. Factors such as rapid growth in pharmaceutical and biotechnology industries, strong R&D investments in the life sciences industry, high incidence of chronic diseases and increasing number of new drug launches are driving the market growth. However, the high cost of biologics and biosimilars products, development of expensive equipment for viral inactivation are inhibiting the marketspace.
Based on method, the Alkylating agent method segment is considered as the robust & efficient method for inactivation of variety of enveloped viruses. Alkylating agents are monofunctional or bifunctional. Two mechanisms exist for viral inactivation with alkylating agents. One mechanism involves the modification of proteins, which would cause inhibition of viral cell entry or the release of the genome. Also, Formalin and β-propiolactone (β-PL) are used for inactivation of viruses via chemical reaction along with viral capsid proteins and nucleic acids. Alkylating agents permeate the protein capsid of viruses and chemically inactivate the nucleic acid. The alkylating agent N-acetyl-aziridine is a virus inactivate that has been used in vaccine preparation. Based on product, the usage of kits and reagents has increased tremendously. Two nucleic acid extraction buffers available commercially are used to inactivate the viral stocks. These are TRIzol® LS reagent (Invitrogen Corp.) and AVL Buffer from the Qiamp viral RNA mini kit (Qiagen). North America has dominated the market during the forecast period due to adoption of many methods by blood testing centre. According to the FDA, 41 novel drugs were approved. Increase in funding has also resulted in growth in number of FDA approvals over the recent years. Some of the key players in Global Viral Inactivation market are Macopharma SA, Charles River Laboratories International, Inc., Clean Cells Inc., Danaher Corporation, Merck KGAA, Parker Hannifin Corporation, Rad Source Technologies, Inc., SGS SA, Sartorius AG, Texcell, Inc., Viral Inactivated Plasma Systems SA, Wuxi Pharmatech (Cayman) Inc., Shandong Weigao Group Medical Polymer Company Limited, Cerus Corporation, Terumo BCT, Inc, BioReliance, Thermo Fisher Scientific Inc. and Macopharma SA.
End Users Covered: -Blood banks and Hospitals -Academic research institutes -Pharmaceutical and Biotechnology companies -Contract Research Organizations -Other End Users
Regions Covered: -North America US Canada Mexico -Europe Germany UK Italy France Spain Rest of Europe -Asia Pacific Japan China India Australia New Zealand South Korea Rest of Asia Pacific -South America Argentina Brazil Chile Rest of South America -Middle East & Africa Saudi Arabia UAE Qatar South Africa Rest of Middle East & Africa
Company Profiling 11.1 Macopharma SA 11.2 Charles River Laboratories International, Inc. 11.3 Clean Cells Inc. 11.4 Danaher Corporation 11.5 Merck KGAA 11.6 Parker Hannifin Corporation 11.7 Rad Source Technologies, Inc. 11.8 SGS SA 11.9 Sartorius AG 11.10 Texcell, Inc. 11.11 Viral Inactivated Plasma Systems SA 11.12 Wuxi Pharmatech (Cayman) Inc. 11.13 Shandong Weigao Group Medical Polymer Company Limited 11.14 Cerus Corporation 11.15 Terumo BCT, Inc. 11.16 BioReliance 11.17 Thermo Fisher Scientific Inc. 11.18 Macopharma SA
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
